Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05397769
Other study ID # B2022-203-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 8, 2022
Est. completion date December 31, 2026

Study information

Verified date August 2022
Source Sun Yat-sen University
Contact Fei Han
Phone 13822113698
Email hanfei@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date December 31, 2026
Est. primary completion date June 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - ECOG 0-1 - histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx - stage III-IVa (AJCC/UICC 8th ), untreated NPC patients - NE= 1.5×10E9/L, HGB = 100g/L and PLT =100×10E9/L - ALT= 1.5 upper limit of normal (ULN), AST= 1.5ULN and bilirubin = 1.5ULN - creatinine<1.5×ULN Exclusion Criteria: - recurrent or metastatic NPC patients - histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx - already received radiation or chemotherapy - pregnant or lactating women, or women of childbearing age without birth control - HIV (+) - had other cancers before - used immune checkpoint inhibitor(CTLA-4?PD-1?PD-L1 etc.) before - complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose - with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included) - use of massive dose of glucocorticoids within 4 weeks before enrollment - laboratory test values do not meet relevant standards within 7 days before enrollment - significantly lower functions of heart, liver, lung, kidney and bone marrow - serious or uncontrolled medical diseases or infections - participating other clinical trial in the same time - HBsAg (+) and HBV DNA >1×10E3 copiers /mL - HCV (+) unless HCV RNA PCR(-) - with any other treatment contraindications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Envafolimab Plus Chemoradiotherapy
Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year progression free survival time from the randomization to the first disease progression or death 3-year
See also
  Status Clinical Trial Phase
Recruiting NCT04539600 - Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer Phase 2
Completed NCT04473716 - Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Phase 1
Recruiting NCT06093438 - Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT04446130 - Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Phase 3
Recruiting NCT02924909 - Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer Phase 2
Active, not recruiting NCT04384627 - Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Phase 3
Recruiting NCT05114707 - Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses Phase 2
Recruiting NCT04083911 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 Phase 3
Recruiting NCT04087967 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients Phase 3